logo







Home>Companies>Tcr2-therapeutics-nas-tcrr


Tcr2 therapeutics (nas: tcrr)

Tcr2 therapeutics (nas: tcrr)



TCR2 Therapeutics (NAS: TCRR) is a biotechnology company focused on developing innovative T cell therapies for cancer patients with solid tumors through its proprietary TRuC-T cells that enhance T cell receptor signaling to specifically target and eliminate cancer cells.
Sign up today to get real-time market insights on Tcr2 therapeutics (nas: tcrr) and hundreds of other pre-IPO companies



Tcr2 therapeutics (nas: tcrr) Overview

Cambridge, MA, United States
2015
Biotech
https://www.tcr2.com



Tcr2 therapeutics (nas: tcrr) Live Market Data

$00000000
$00000000




Tcr2 therapeutics (nas: tcrr) Funding Rounds



RoundDateAmount RaisedValuationInvestorsSources
Merger/Acquisition3/6/2023
IPO2/14/2019
Series B3/21/2018
Series A12/7/2016
Early Stage VC1/1/2015








Tcr2 therapeutics (nas: tcrr) 409a Valuations



DatePrice per shareEst. ValuationFilling
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Sign up to access Tcr2 therapeutics (nas: tcrr) data




Tcr2 therapeutics (nas: tcrr) Filings



TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign up to access Tcr2 therapeutics (nas: tcrr) data








Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


DisclaimerAll investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.